← Leaderboards
Medhi Wangpaichitr
Miami Va Health Care System
$0
Attributed
$0
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $0 · FY2013–25$1$1$1$0$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
VA$0 · 3
By mechanism
I01$0 · 2
IK2$0 · 1
Top collaborators
- Andrew Schally1 shared
Others in their field
Top investigators on “Cessation Of Life”
- David R. Weir · University Of Michigan At Ann Arbor$345,522,974
- John M Lachin · George Washington University$134,302,892
- David M Nathan · Massachusetts Institute Of Technology$127,791,564
- Judith S Hochman · New York University School Of Medicine$112,898,313
- Jeffrey H Samet · Boston University Medical Campus$91,739,367
- Judith S. Currier · University Of California Los Angeles$85,330,415
Research focus
Cessation Of LifeVeteransResistanceCellsProductionNon-Small-Cell Lung CarcinomaNovel Therapeutic InterventionMalignant Neoplasm Of LungTumorAnalogMetabolicReactive Oxygen SpeciesAffectPharmaceutical PreparationsNovel StrategiesCisplatinChemotherapyFuturePathway InteractionsCancer PatientPlatinumEarly TreatmentLeadCell Death
Grant awards (11)
Hi-jacking the kynurenine pathway: A new therapeutic approach used to treat cisplatin resistant lung cancer that evades immune surveillance and proliferates with increased ROS levels$0
I01 · FY2025 · VA · contact PI
Development of new therapies for cancer and other diseases and conditions using analogs of growth hormone-releasing hormones (GHRH)$0
I01 · FY2023 · VA · contact PI
Hi-jacking the kynurenine pathway: A new path used by cisplatin resistant non-small cell lung cancer to survive and evade immune surveillance under high ROS$0
I01 · FY2021 · VA · contact PI
Hi-jacking the kynurenine pathway: A new path used by cisplatin resistant non-small cell lung cancer to survive and evade immune surveillance under high ROS$0
I01 · FY2020 · VA · contact PI
Hi-jacking the kynurenine pathway: A new path used by cisplatin resistant non-small cell lung cancer to survive and evade immune surveillance under high ROS$0
I01 · FY2019 · VA · contact PI
Hi-jacking the kynurenine pathway: A new path used by cisplatin resistant non-small cell lung cancer to survive and evade immune surveillance under high ROS$0
I01 · FY2018 · VA · contact PI
Metabolic reprogramming: A new paradigm for targeting cisplatin resistant cells$0
IK2 · FY2017 · VA · contact PI
Metabolic reprogramming: A new paradigm for targeting cisplatin resistant cells$0
IK2 · FY2016 · VA · contact PI
Metabolic reprogramming: A new paradigm for targeting cisplatin resistant cells$0
IK2 · FY2015 · VA · contact PI
Metabolic reprogramming: A new paradigm for targeting cisplatin resistant cells$0
IK2 · FY2014 · VA · contact PI
Metabolic reprogramming: A new paradigm for targeting cisplatin resistant cells$0
IK2 · FY2013 · VA · contact PI